A 46% premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at technology that fits into its own expertise.
A 46% premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at technology that fits into its own expertise.
